Heart failure & cardiomyopathies
Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial
Authors' conclusion
Outpatient worsening HF was frequent in patients with ATTR-CM in HELIOS-B, was associated with increased mortality, and reduced by vutrisiran.
Study context
- Population
- Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in HELIOS-B
- Comparison
- Vutrisiran vs placebo; outpatient worsening heart failure (HF) vs none
- Primary endpoint
- Outpatient worsening HF (oral loop diuretic intensification or initiation): association with composite of all-cause mortality and recurrent CV events, all-cause mortality, and vutrisiran effect
- Follow-up
- 36 months
Methodological detailsdouble-blind
- Double-blind
Primary result
As reported in the abstract
Outpatient worsening HF: frequency and prognosis
Outpatient worsening HF vs No outpatient worsening HFHazard ratio (95% CI)
All-cause mortality and CV events
2.58(2.04–3.27)
All-cause mortality
2.45(1.70–3.52)
- ≥1 outpatient worsening HF
- 321 patients (49.1%)
- ≥1 cardiovascular (CV) event(s)
- 245 (37.5%)
- Died
- 120 (18.3%)
- No events
- 237 patients (36.2%)
Further findings
| Outcome | Estimate | |
|---|---|---|
| Rate of outpatient worsening HF (recurrent events) · double-blind period | relative rate ratio 0.66 (95% CI 0.56–0.78) | |
| Composite of all-cause mortality, CV events and outpatient worsening HF | HR 0.69 (95% CI 0.57–0.83) | |
| 0.512Ratio (log scale) |
Original publication
Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial. J Am Coll Cardiol. Published 18 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →